AbbVie Revenue 2010-2019 | ABBV

AbbVie annual/quarterly revenue history and growth rate from 2010 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • AbbVie revenue for the quarter ending March 31, 2019 was $7.828B, a 1.34% decline year-over-year.
  • AbbVie revenue for the twelve months ending March 31, 2019 was $32.647B, a 10.25% increase year-over-year.
  • AbbVie annual revenue for 2018 was $32.753B, a 16.08% increase from 2017.
  • AbbVie annual revenue for 2017 was $28.216B, a 10.06% increase from 2016.
  • AbbVie annual revenue for 2016 was $25.638B, a 12.16% increase from 2015.
AbbVie Annual Revenue
(Millions of US $)
2018 $32,753
2017 $28,216
2016 $25,638
2015 $22,859
2014 $19,960
2013 $18,790
2012 $18,380
2011 $17,444
2010 $15,638
2009 $14,214
AbbVie Quarterly Revenue
(Millions of US $)
Q1 2019 $7,828
Q4 2018 $8,305
Q3 2018 $8,236
Q2 2018 $8,278
Q1 2018 $7,934
Q4 2017 $7,739
Q3 2017 $6,995
Q2 2017 $6,944
Q1 2017 $6,538
Q4 2016 $6,796
Q3 2016 $6,432
Q2 2016 $6,452
Q1 2016 $5,958
Q4 2015 $6,400
Q3 2015 $5,944
Q2 2015 $5,475
Q1 2015 $5,040
Q4 2014 $5,452
Q3 2014 $5,019
Q2 2014 $4,926
Q1 2014 $4,563
Q4 2013 $5,111
Q3 2013 $4,658
Q2 2013 $4,692
Q1 2013 $4,329
Q4 2012 $5,206
Q3 2012 $4,508
Q2 2012 $4,493
Q1 2012 $4,173
Q4 2011 $4,864
Q3 2011 $4,409
Q2 2011 $4,274
Q1 2011 $3,897
Q4 2010
Q4 2009
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $100.896B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.653B 15.18
Pfizer (PFE) United States $239.411B 13.98
Roche Holding AG (RHHBY) Switzerland $235.547B 0.00
Novartis AG (NVS) Switzerland $216.260B 18.59
Merck (MRK) United States $212.897B 18.33
Novo Nordisk (NVO) Denmark $118.280B 19.63
Eli Lilly (LLY) United States $105.180B 19.52
Sanofi (SNY) France $104.721B 12.91
AstraZeneca (AZN) United Kingdom $103.165B 11.88
GlaxoSmithKline (GSK) United Kingdom $102.722B 13.02
Bristol-Myers Squibb (BMY) United States $72.053B 10.64
Bayer (BAYRY) Germany $62.123B 9.05
H Lundbeck (HLUYY) Denmark $7.808B 11.27